Transgenomic Eyes COLD-PCR as Key Revenue Driver via Pharma Pacts, Dx Sales and Services

Following the release of its Q4 and full-year financial results, Transgenomic updated investors on how its COLD-PCR technology may drive future revenues through diagnostic kit sales and testing services, and said that it has signed contracts with three pharma companies to explore applications for the technology.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.